文献速递消化道肿瘤放疗

早期直肠癌直肠系膜放疗:一种新型靶区

Mesorectal radiotherapy for early stage rectal cancer: A novel target volume.
PubMed 文献 · Clin Transl Radiat Oncol · 2020-02-04

随着人群筛查推广,直肠癌早期诊断增多,但标准治疗仍沿用晚期的大范围手术。STAR-TREC试验研究(化)放疗器官保留,将小mrT1-3bN0V0M0肿瘤随机分为标准TME、SCRT器官保留或CRT器官保留三组。该试验采用仅照射直肠系膜及肿瘤水平骶前淋巴结的新靶区,上界至S2-3间隙,下界至肿瘤下2cm,排除侧方淋巴结和直肠上动脉淋巴结,预期降低肠道、膀胱、肛门括约肌及盆底神经血管丛剂量,减少急性和晚期毒性并改善功能结局。

要点

  • 早期直肠癌器官保留治疗中,STAR-TREC试验采用仅照射直肠系膜及肿瘤水平骶前淋巴结的靶区。
  • 新靶区上界至S2-3间隙,下界至肿瘤下2cm,排除侧方淋巴结和直肠上动脉淋巴结。
  • 该靶区联合动态弧治疗等现代技术可降低肠道、膀胱、肛门括约肌及盆底神经血管丛剂量。

核心结论

  • STAR-TREC试验采用仅照射直肠系膜及肿瘤水平骶前淋巴结的新型靶区,旨在早期直肠癌器官保留治疗中降低正常组织剂量和毒性。

研究设计与样本

  • STAR-TREC是一项国际多中心随机试验,研究(化)放疗器官保留,将小mrT1-3bN0V0M0肿瘤患者随机分为标准TME、SCRT器官保留和CRT器官保留三组。

主要发现

  • 新靶区包括直肠系膜及肿瘤水平骶前淋巴结,上界至S2-3间隙,下界至肿瘤下2cm,排除侧方淋巴结和直肠上动脉淋巴结。
  • 与传统照射体积相比,新靶区使肠道、膀胱、肛门括约肌及下骨盆神经血管丛剂量显著降低,尤其联合动态弧治疗时。

关键数值与推荐

  • 靶区上界为S2-3间隙水平,下界为肿瘤下2cm。
  • 新靶区排除侧方淋巴结和直肠上动脉淋巴结。

临床怎么用

  • 该靶区适用于STAR-TREC试验入选的小mrT1-3bN0V0M0早期直肠癌器官保留治疗。
  • 实施时需配合STAR-TREC试验的广泛质量保证程序。

局限性

  • 原文未报告新靶区的临床结局数据,仅描述其 rationale 和预期毒性降低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

With the introduction of population-based bowel cancer screening, rectal cancer is diagnosed at earlier stages, yet standard treatment still requires the same extensive surgery that is used for more advanced stages. Organ preserving treatment is rapidly developing and is subject of investigation in numerous clinical trials. The STAR-TREC trial is an international, multi-centre randomised trial investigating organ preservation using (chemo)radiotherapy. Patients with small mrT1-3bN0V0M0 tumours are randomized between three arms: standard TME, organ preservation with SCRT or with CRT. In this trial, the clinical target volume has been tailored to the early staged disease of the included patients. This mesorectal irradiation volume includes the mesorectum and pre-sacral lymph nodes at the level of the tumour, two centimetres below and cranially up to the S2-3 interspace level. In contrast to conventional irradiation volumes, the lateral lymph nodes and the nodes along the superior rectal artery are excluded. As a result, the dose to the bowel, bladder, anal sphincter and the neurovascular plexus in the lower pelvis is substantially decreased, especially when combined with modern irradiation techniques, such as dynamic arc therapy. These lower doses are expected to lead to decreasing acute and late toxicity and beneficial functional outcomes. The implementation of this novel target volume will be accompanied by an extensive quality assurance program in the STAR-TREC trial. We describe the rationale behind the novel, mesorectal only radiotherapy treatment used in the STAR-TREC trial specifically tailored for early stage disease, with the goal of organ preservation.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Peters FP, Teo MTW, Appelt AL, et al. Mesorectal radiotherapy for early stage rectal cancer: A novel target volume. Clin Transl Radiat Oncol. 2020. PMID: 32099912. doi:10.1016/j.ctro.2020.02.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。